Win-Win Fine Chemical Expert

Hengrui’s Phase III Head-to-Head Study of Ribupatide vs. Semaglutide Succeeds

On August 4, Hengrui Medicine announced positive top-line results from the Phase III study (HRS9531-303) in China evaluating Ribupatide injection (HRS9531/KAI-9531-T) head-to-head against semaglutide(Cas #910463-68-2) injection for glycemic control. Both the 4mg and 2mg dosage groups of Ribupatide injection met the pre-specified primary endpoint: the change in HbA1c from baseline was non-inferior to that of the 1mg semaglutide injection group. Based on these results, Hengrui Medicine plans to submit a New Drug Application (NDA) in China in the near future for Ribupatide injection for glycemic control in adults with type 2 diabetes.

Read More...

CPHI China 2026

Our company will attend “CPhI China” in Shanghai, from Jun 16th to 18th, 2026. We welcome you to visit and discover our latest services and capabilities. To make an appointment, please contact email: sales@win-winchemical.com.

Read More...

A Tirezepatide Equivalent! Major Domestic Weight-Loss Drug Achieves Topline Results

On May 5, 2026, Borui Pharmaceutical, an innovative drug company listed on the STAR Market, announced that its independently developed GLP-1/GIP dual receptor agonist—BGM0504 Injection—achieved positive topline results in a Phase III clinical study (Project No.: BGM0504-III-WL) designed to evaluate its efficacy and safety in overweight or obese subjects. BGM0504 is a GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) dual receptor agonist independently developed by the company; it activates downstream pathways to elicit biological effects such as blood glucose control, weight loss, and the treatment of metabolic dysfunction-associated steatohepatitis (MASH).

Read More...

The Domestic GLP-1 Arena: Has a "Trump Card" Just Emerged?

As global competition within the GLP-1 landscape reaches a fever pitch, weight loss is no longer the sole objective; rather, cardiovascular-metabolic benefits and tolerability have emerged as key differentiators. Recently, Borui Pharmaceutical announced positive top-line results from BGM0504-III-WL—a Phase III clinical trial evaluating BGM0504 Injection, its independently developed dual GLP-1/GIP receptor agonist. The data reveals that the drug not only demonstrated exceptional efficacy in terms of weight loss and waist circumference reduction but also exhibited superior comprehensive capabilities in cardiovascular-metabolic regulation. Furthermore, it boasted an extremely low discontinuation rate, and—remarkably—led to an increase rather than a decrease in bone mineral density. These results position BGM0504 as a strong contender to become the next "trump card" product in the GLP-1 market.

Read More...

Global’s First Biased GLP-1 Weight-Loss Drug, Xianweiying, Approved for Launch!

On March 6, 2026, a biopharmaceutical company dedicated to the discovery and development of innovative therapies for metabolic diseases announced that Enoglutide Injection (Xianweiying)—the world’s first cAMP-biased GLP-1 receptor agonist—has received market approval from the National Medical Products Administration (NMPA). It is indicated for the long-term weight management of overweight or obese adults, to be used in conjunction with a reduced-calorie diet and increased physical activity.

Read More...

Hehuang Pharmaceuticals' Furoquitinib 'Approved for Market by FDA

On November 9th, Hehuang Pharmaceutical announced FRUZAQLA ? Furuintinib has been approved by the FDA for marketing, becoming the first and only highly selective inhibitor for all three types of VEGF receptor kinases approved for the treatment of metastatic colorectal cancer in the United States, regardless of the patient's biomarker status.

Read More...